Literature DB >> 15709483

The interaction of amyloid-beta with ApoE.

Donald B Carter1.   

Abstract

Brain plaque deposition in the form of amyloid-beta (Abeta) peptide is a pathological hallmark of Alzheimer's disease (AD). Apolipoprotein E (ApoE) is thought to be involved in plaque formation. Individuals afflicted with AD carrying the ApoE4 isoform have shown a greater number of Abeta plaques when compared to ApoE3 carriers, and inheritance of an ApoE4 allele increases the risk of AD when compared to ApoE2 and ApoE3 carriers. The role of ApoE in the pathogenesis of AD is not well understood but a hypothesis gaining widespread support is that ApoE is involved in deposition or clearance of Abeta by direct protein-to-protein interaction. We have established that various human Abeta conformations apparent during spontaneous aggregation confer differing degrees of binding to the three ApoE isoforms. When associated with lipid, ApoE4 bound preferentially to an intermediate aggregated form of Abeta and had higher avidity than did ApoE2 or ApoE3.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15709483     DOI: 10.1007/0-387-23226-5_13

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  27 in total

1.  Alzheimer's disease: ageing-related or age-related? New hypotheses from an old debate.

Authors:  Orso Bugiani
Journal:  Neurol Sci       Date:  2011-05-13       Impact factor: 3.307

2.  Vascular disease and risk factors are associated with cognitive decline in the alzheimer disease spectrum.

Authors:  Natacha Lorius; Joseph J Locascio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Anand Viswanathan; Gad A Marshall
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jan-Mar       Impact factor: 2.703

Review 3.  Biomarkers in Alzheimer's disease: past, present and future.

Authors:  Katarzyna Gustaw-Rothenberg; Alan Lerner; David J Bonda; Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

4.  Regulation of IL-1β-induced cyclooxygenase-2 expression by interactions of Aβ peptide, apolipoprotein E and nitric oxide in human neuroglioma.

Authors:  Anju S Samy; Orisa J Igwe
Journal:  J Mol Neurosci       Date:  2011-11-19       Impact factor: 3.444

5.  Apolipoprotein E-dependent differences in innate immune responses of maturing human neuroepithelial progenitor cells exposed to HIV-1.

Authors:  Rebeca Geffin; Ricardo Martinez; Roberto Perez; Biju Issac; Micheline McCarthy
Journal:  J Neuroimmune Pharmacol       Date:  2013-06-07       Impact factor: 4.147

6.  Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice.

Authors:  Tom Van Dooren; David Muyllaert; Peter Borghgraef; Annelies Cresens; Herman Devijver; Ingrid Van der Auwera; Stefaan Wera; Ilse Dewachter; Fred Van Leuven
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

7.  A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution.

Authors:  Jitka Petrlova; Hyun-Seok Hong; Daniel A Bricarello; Ghimire Harishchandra; Gary A Lorigan; Lee-Way Jin; John C Voss
Journal:  Proteins       Date:  2011-02

Review 8.  Etiology and pathogenesis of late-onset Alzheimer's disease.

Authors:  Brian J Balin; Alan P Hudson
Journal:  Curr Allergy Asthma Rep       Date:  2014-03       Impact factor: 4.806

9.  Genetic influences on cognition in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Erik D Roberson; Gerard D Schellenberg; David G Standaert; David R Shprecher; Benzi M Kluger; Irene Litvan
Journal:  Mov Disord       Date:  2017-10-27       Impact factor: 10.338

10.  Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses.

Authors:  Anatoliy I Yashin; Fang Fang; Mikhail Kovtun; Deqing Wu; Matt Duan; Konstantin Arbeev; Igor Akushevich; Alexander Kulminski; Irina Culminskaya; Ilya Zhbannikov; Arseniy Yashkin; Eric Stallard; Svetlana Ukraintseva
Journal:  Exp Gerontol       Date:  2017-10-26       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.